氧化三甲胺是潜在的心力衰竭治疗靶点和预后标志物  

Trimethylamine N-oxide:potential therapeutic targets and prognostic biomarkers of heart failure

作　　者：周奕廷 郁志明[1] ZHOU Yiting;YU Zhiming(Department of Cardiology,Wuxi People′s Hospital Affiliated to Nanjing Medical University,Wuxi 214023,China)

机构地区：[1]南京医科大学附属无锡市人民医院心血管内科,江苏无锡214023

出　　处：《南京医科大学学报（自然科学版）》2023年第2期291-296,共6页Journal of Nanjing Medical University(Natural Sciences)

基　　金：太湖人才计划高端人才[(2020-2024)-2021(2020THRC-CD-YZM-2021)]。

摘　　要：研究表明,肠道菌群及其代谢产物参与了各类心血管疾病的发生发展过程,且与疾病的预后进展有着密不可分的关系。在心力衰竭患者中,内脏低灌注会导致肠道缺血,肠道通透性发生改变,进而使细菌及其毒素易位入血,引发局部或全身炎症反应。肠道菌群代谢产物氧化三甲胺(trimethylamine N-oxide,TMAO)参与了心力衰竭的病理过程,如加剧心肌肥厚和纤维化、诱发炎症反应、通过影响肾功能恶化心衰。文章就氧化三甲胺为靶点的心力衰竭治疗及其作为心力衰竭预后标志物进行综述。Studies reveal that the gut microbiota and its metabolites play an important role in the pathogenesis and progression of various cardiovascular diseases,and are inseparably related to the prognosis of the disease.In patients with heart failure,splanchnic hypoperfusion leads to intestinal ischemia and alters intestinal permeability,and then translocates bacteria and their toxins into the blood circulation,triggering local orsystemic inflammatory responses.Trimethylamine N-oxide(TMAO),as a metabolite of gut microbiota,is involved in the pathological process of heart failure,such as exacerbating cardiac hypertrophy and fibrosis,inducing inflammatory responses,and worsening heart failure by affecting renal function.This article reviews trimethylamine N-oxideas as the therapeutic target of heart failure and as a prognostic marker of heart failure.

关 键 词：肠道菌群 氧化三甲胺 心力衰竭 治疗 预后标志物 

分 类 号：R541.6[医药卫生—心血管疾病]